Skip to main content
OB

OneCare Biotechnologies

OneCare Biotechnologies develops blood‑based biomarker platforms that add objective, AI‑enhanced precision to the diagnosis and monitoring of neuropsychiatric disorders such as psychosis, mood disorders, depression, and bipolar disorder.

Montreal, QuebecFounded 202110300+ followers
Updated 1 month ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current psychiatric diagnosis and treatment selection rely heavily on subjective symptom reporting and clinician judgment, leading to inconsistent assessments, delayed identification of disorders, and trial‑and‑error medication choices. This lack of objective biomarkers hampers early detection and precise monitoring of conditions such as psychosis, mood disorders, depression, and bipolar disorder.

Solution

OneCare Biotechnologies creates blood‑based biomarker platforms that provide objective, quantifiable measures of neuropsychiatric disorders. By combining molecular profiling of blood samples with AI‑driven data analytics, the company generates diagnostic and treatment‑response signatures that are clinically validated across diverse populations. These tools enable clinicians to confirm diagnoses, stratify patients, and track disease progression with greater accuracy than symptom‑based assessments alone. The platform is designed for integration into psychiatric practice and research settings, supporting more personalized treatment decisions and facilitating large‑scale mental‑health studies.

Target Audience

Primary customers are psychiatric clinicians, mental‑health clinics, and research institutions seeking objective diagnostic tools for neuropsychiatric disorders.

Features

  • Molecular assays that detect disease‑specific signatures in peripheral blood for psychosis, depression, bipolar disorder, and other mood disorders
  • AI models trained on inclusive, multi‑ethnic datasets to ensure diagnostic performance across diverse patient groups
  • Clinically validated algorithms that predict treatment response and disease trajectory
  • Turnkey workflow from blood draw to cloud‑based report, delivering results within a clinically actionable timeframe
  • Secure data handling and compliance with health‑information privacy standards
  • Compatibility with electronic health record systems for seamless integration into existing clinical workflows
This profile is AI-generated and may contain inaccuracies.